Download PDF
Thromb Haemost 1966; 16(03/04): 707-722
DOI: 10.1055/s-0038-1655656
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Some Effects of Purified Autoprothrombin C in Blood Clotting[*]

G Müller-Berghaus
1   From the Department of Physiology and Pharmacology, Wayne State University, School of Medicine, Detroit, Michigan, U.S.A.
,
W. H Seegers
1   From the Department of Physiology and Pharmacology, Wayne State University, School of Medicine, Detroit, Michigan, U.S.A.
› Author Affiliations
Further Information

Publication History

Publication Date:
26 June 2018 (online)

    Permissions and Reprints

Summary

Purified autoprothrombin C was added to rabbit blood or recalcified plasma in order to measure the exact influence on clotting time. At a concentration of 10 u of autoprothrombin C per ml blood there was clotting in 13 sec. At that concentration recalcified plasma clotted in 7 to 8 sec. In the acceleration of the whole blood clotting time with autoprothrombin C, the effect was greater in glass tubes than in silicone coated tubes. The difference was probably due to lipids from platelets. With autoprothrombin C at a concentration of 10 u/ml reaction mixture, the prothrombin time and partial thromboplastin time of plasma was brought down to 3 to 4 sec. The partial thromboplastin time supplied the most sensitive conditions for detecting autoprothrombin C activity. Less than 2 × 10−5 micrograms of autoprothrombin C were detected. Rabbits that were treated with Coumadin had their prothrombin concentration reduced to 9 u/ml plasma, as measured by two-stage analysis. Such plasma yielded twice as much thrombin when purified autoprothrombin C and purified Ac-globulin were used in the assay to determine the thrombin potential. Even when the prothrombin concentration was brought to low levels with Coumadin a partial thromboplastin time or prothrombin time of 7 sec was easily obtained by using autoprothrombin C as procoagulant. The important effect of Coumadin or related drugs is the reduction of prothrombin concentration. This involves a lowering of the autoprothrombin C potential as well as the thrombin potential of plasma, and also the amount of inhibitor that can be obtained from prothrombin.

Normal blood was found to contain prethrombin in small amounts as well as prothrombin. The synthesis of prothrombin was stopped with Coumadin and it is likely that the residual prothrombin was in part utilized by degradation to prethrombin, inhibitor and autoprothrombin III. At the height of the anticoagulant effect the prethrombin concentration was higher than the prothrombin concentration. With the resumption of prothrombin synthesis, when vitamin K was given, it may be that prethrombin, inhibitor, and autoprothrombin III was first produced in the liver and some of the latter entered the blood stream to compensate for substrate deficiency. Free autoprothrombin III would account for the short prothrombin time observed before prothrombin concentration rose.

* This investigation was supported by research grant HE-05141-06 from the National Heart Institute, National Institution of Health, U. S. Public Health Service.


 

  • References

  • 1 Aoki N, Harmison C. R, Seegers W. H. Properties of bovine Ac-globulin concentrates and methods of preparation. Canad. J. Biochem 41: 2409 1963;
    PubMedGoogle Scholar
  • 2 Cole E. R, Marciniak E, Seegers W. H. Procedure for the quantitative determination of autoprothrombin C. Thrombos. Diathes. haemorrh. (Stuttg.) 8: 434 1962;
    PubMedGoogle Scholar
  • 3 Davie E. W, Ratnoff O. D. Waterfall sequence for intrinsic blood clotting. Science 145: 1310 1964;
    CrossrefPubMedGoogle Scholar
  • 4 Hartert H. Blutgerinnungsstudien mit der Thrombelastographie, einem neuen Untersuchungsverfahren. Klin. Wschr 26: 577 1948;
    CrossrefPubMedGoogle Scholar
  • 5 Kowarzyk H, Marciniak E. The significance of prothrombin derivatives. Proc. of the 8th Congr. of Europ. Soc. Haematol., Vienna, 1961. p. 402
    PubMedGoogle Scholar
  • 6 Macfarlane R. G. An enzyme cascade in blood clotting mechanism, and its function as a biochemical amplifier. Nature (Lond.) 202: 498 1964;
    CrossrefPubMedGoogle Scholar
  • 7 Mammen E. F. The purification and properties of platelet cofactor I (factor VIII). Vox Sang 5: 414 1963;
    PubMedGoogle Scholar
  • 8 Mammen E. F, Thomas W. R, Seegers W. H. Activation of purified prothrombin to autoprothrombin I or autoprothrombin II (platelet cof actor II) or autoprothrombin II-A. Thrombos. Diathes. haemorrh. (Stuttg.) 5: 218 1960;
    PubMedGoogle Scholar
  • 9 Marciniak E, Seegers W. H. Autoprothrombin C: A second enzyme from prothrombin. Canad. J. Biochem 40: 597 1962;
    PubMedGoogle Scholar
  • 10 Marciniak E, Seegers W. H. Experiments with prothrombin, prethrombin, autoprothrombin III and plasma with prothrombin related deficiencies. New Istanbul Contr. clin. Sci 8: 117 1965;
    PubMedGoogle Scholar
  • 11 Marciniak E, Seegers W. H. Characteristics of the prethrombin subunit of prothrombin. Fourteenth annual symposium on blood. Jan. 21 and 22, 1966. Thrombos. Diathes. haemorrh. (Stuttg.) 15: 625 1966;
    PubMedGoogle Scholar
  • 12 Marciniak E, Seegers W. H. Prethrombin as a new subunit of prothrombin. Nature (Lond.) 209: 5023 1966;
    PubMedGoogle Scholar
  • 13 Milstone J. H. Thrombokinase as prime activator of prothrombin: historical perspectives and present status. Fed. Proc 23: 742 1964;
    PubMedGoogle Scholar
  • 14 Rodriguez-Erdmann F. Über eine einfache Methode zur wiederholten Blutgerinnung beim Kaninchen. Pflügers Archiv ges. Physiol 269: 306 1959;
    PubMedGoogle Scholar
  • 15 Schröer H, Heene D. L, Seegers W. H. Addition of prothrombin to blood from dogs receiving dicumarol. Thrombos. Diathes. haemorrh. (Stuttg.) 13: 187 1965;
    PubMedGoogle Scholar
  • 16 Seegers W. H. Activation of purified prothrombin. Proc. Soc. exp. Biol. (N. Y.) 72: 677 1949;
    CrossrefPubMedGoogle Scholar
  • 17 Seegers W. H. The purification of prothrombin. Ree. Chem. Progr 13: 143 1952;
    PubMedGoogle Scholar
  • 18 Seegers W. H. Prothrombin. Harvard Univ. Press; Cambridge, Mass.: 1962: 321.
    Google Scholar
  • 19 Seegers W. H, Gole E. R, Aoki N. Function of Ac-globulin and lipid in blood clotting. Canad. J. Biochem 41: 2441 1963;
    PubMedGoogle Scholar
  • 20 Seegers W. H, Heene D. L, Marciniak E. Activation of purified prothrombin in ammonium sulfate solutions: purification of autoprothrombin C. Thrombos. Diathes. haemorrh. (Stuttg.) 15: 1 1966;
    PubMedGoogle Scholar
  • 21 Seegers W. H, Landaburu R. H, Fenichel R. F. Isolation of platelet cofactor I from plasma and some properties of the preparation. Amer. J. Physiol 190: 1 1957;
    PubMedGoogle Scholar
  • 22 Seegers W. H, Levine W. G, Shepard R. S. Further studies on the purification of thrombin. Canad. J. Biochem 36: 603 1958;
    PubMedGoogle Scholar
  • 23 Seegers W. H, Marciniak E. Autoprothrombin C in irregular blood clotting. Thrombos. Diathes. haemorrh. (Stuttg.) 8: 1 1962;
    PubMedGoogle Scholar
  • 24 Seegers W. H, Marciniak E. Some activation characteristics of the prethrombin subunit of prothrombin. Life Sciences 4: 1721 1965;
    CrossrefPubMedGoogle Scholar
  • 25 Seegers W. H, Marciniak E, Heene D. Enzyme basis of prothrombin activation (blood clotting) with an analysis of hemophilia A. Tex. Rep. Biol. Med 23: 675 1965;
    PubMedGoogle Scholar
  • 26 Ware A. G, Seegers W. H. Two-stage procedure for the quantitative determination of prothrombin concentration. Amer. J. clin. Path 19: 471 1949;
    PubMedGoogle Scholar
  • 27 Warner E. D, Brinkhous K. M, Smith H. P. A quantitative study on blood clotting; prothrombin fluctuations under experimental conditions. Amer. J. Physiol 114: 667 1936;
    PubMedGoogle Scholar